Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tonix Pharma Limited has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners and 6 distinct art units, so the prosecution workload is distributed across separate examination assignments rather than concentrated in one unit.
TAYLOR, LIA ELAN is the busiest examiner, with 1 pending office action. The profile supports coordinating responses across the broader examiner and art-unit mix while addressing that examiner’s matter separately.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 4 (67%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYLOR, LIA ELAN | 1 | 64.2% | +29.5% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| MIDDLETON, DANAYA L | 1 | 49.5% | +48.8% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623710 | ANTI-CD154 ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265525 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | CHONG, YONG SOO | 26d |
| 17623710 | ANTI-CD154 ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
| 18271098 | METHODS OF INDUCING IMMUNE TOLERANCE WITH MODIFIED ANTI-CD154 ANTIBODIES | TAYLOR, LIA ELAN | — |
| 18212500 | CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC) | BARSKY, JARED | — |
| 18037815 | CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER | NEAGU, IRINA | — |
| 17269106 | METHODS OF TREATING ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER | BAEK, BONG-SOOK | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1628 | 1 |
| 1623 | 1 |
| 1629 | 1 |
| 1674 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18271098 | METHODS OF INDUCING IMMUNE TOLERANCE WITH MODIFIED ANTI-CD154 ANTIBODIES | TAYLOR, LIA ELAN | 1641 | §103§112DP | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18212500 | CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC) | BARSKY, JARED | 1628 | §103DP | Final Rejection | — | Pending | Jun 21, 2023 |
| 18265525 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | CHONG, YONG SOO | 1623 | §103Other | Final Rejection | 26d | Pending | Jun 06, 2023 |
| 18037815 | CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER | NEAGU, IRINA | 1629 | §103DP | Final Rejection | — | Pending | May 19, 2023 |
| 17623710 | ANTI-CD154 ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §103§112Other | Final Rejection | 70d | Pending | Dec 29, 2021 |
| 17269106 | METHODS OF TREATING ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER | BAEK, BONG-SOOK | 1611 | §103DP | Final Rejection | — | Pending | Feb 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTonix Pharma Limited has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Lia Elan Taylor has the most, with 1 of Tonix Pharma Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
